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ABSTRACT: Low expressions of angiogenic growth factors
delay the healing of diabetic wounds by interfering with the
process of blood vessel formation. Heparin mimetic peptide
nanofibers can bind to and enhance production and activity of
major angiogenic growth factors, including VEGF. In this
study, we showed that heparin mimetic peptide nanofibers can
serve as angiogenic scaffolds that allow slow release of growth
factors and protect them from degradation, providing a new
therapeutic way to accelerate healing of diabetic wounds. We treated wounds in STZ-induced diabetic rats with heparin mimetic
peptide nanofibers and studied repair of full-thickness diabetic skin wounds. Wound recovery was quantified by analyses of re-
epithelialization, granulation tissue formation and blood vessel density, as well as VEGF and inflammatory response
measurements. Wound closure and granulation tissue formation were found to be significantly accelerated in heparin mimetic gel
treated groups. In addition, blood vessel counts and the expressions of alpha smooth muscle actin and VEGF were significantly
higher in bioactive gel treated animals. These results strongly suggest that angiogenic heparin mimetic nanofiber therapy can be
used to support the impaired healing process in diabetic wounds.
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1. INTRODUCTION
Diabetes mellitus is a chronic disease caused either by the
destruction of insulin-producing beta cells in the pancreas
(type-1 diabetes) or insufficient response to secreted insulin
(type-2 diabetes).1 The prevalence of both of types of diabetes
has been on the rise, and the disease may soon become one of
the foremost public health problems that the world will face in
the decades ahead.2 In addition to the direct consequences of a
malfunctioning carbohydrate metabolism, diabetes is associated
with various secondary complications, including severe chronic
ulcers that occur on the feet and sometimes necessitate limb
amputation.3 The healing of other injuries is also delayed in
diabetic patients, and the increase in the prevalence of diabetes
has made it an important necessity to develop appropriate
wound dressings for diabetic wounds. Clinical and experimental
studies showed that the four classical phases of wound healing
do not occur in their typical order and fail to fully perform their
function in diabetic wounds.4 In chronic wounds, the
impairment of the healing process is mostly related to
degradation or diminished expression of growth factors,
which hinders the generation of blood vessels and consequently
prevents the transport of oxygen and nutrients to the wound
area.5,6 A variety of angiogenic growth factors are involved in
the wound healing process, the most important of which is
vascular endothelial growth factor (VEGF); however, the
expression of VEGF is dramatically reduced in diabetic
wounds.7,8 VEGF is vital in stimulating cell proliferation and
strongly influence endothelial tube formation. It has been
demonstrated that the treatment of wound site with VEGF
accelerates wound healing via improved granulation tissue
formation in the rabbit ear and induce angiogenesis in diabetic
mice.9,10
Heparan sulfate proteoglycans (HSPGs) are members of
glycosaminoglycan (GAG) family which are found in the
extracellular matrix and plasma membrane.11 HSPGs modulates
its functions by interacting with a broad variety of angiogenic
growth factors.12 The heparin binding affinity is critical for
stimulation of vasculogenesis and angiogenesis and VEGF plays
an especially vital role in this context. Although HSPGs can be
administered directly to the wound site to improve wound
healing, they have limitations such as vulnerability to enzymatic
degradation, batch-to-batch variation and high heterogeneity.13
It has also been proposed that the failure of treatments of
diabetic wounds using exogenous growth factors such as VEGF
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in clinical trials, might be due to instability of natural materials
in enzyme rich environment.14 However, recent advances in
material sciences and polymer chemistry have resulted in the
development of synthetic biomimetic peptide fibers, an entire
class of new nanomaterials that can mimic the bioactivity of
natural materials. Peptide amphiphiles (PAs) are self-assem-
bling biodegradable materials that have a potential to replicate
the function of native extracellular matrix, and can therefore be
used to enhance the angiogenesis process in diabetic wounds
with greater control over growth factor release kinetics.15
Previously, we reported heparin mimetic PAs (GAG-PA/K-
PA) that are able to induce angiogenesis without the addition
of heparin or exogenous growth factors under both in vitro and
in vivo conditions.16 Furthermore, it has been shown that GAG-
PA/K-PA bioactive nanofibers display strong binding affinities
to VEGF, hepatocyte growth factor (HGF), and fibroblast
growth factor-2 (FGF-2). The high binding capacity of
nanofibers is particularly valuable since they protect growth
factors from degradation and provide a suitable cellular
microenvironment for signaling. Because angiogenesis is the
key component of the wound healing process and is regulated
by of HSPGs, heparin mimetic PAs may also enhance blood
vessel formation in diabetic patients.
Here, we show the effect of heparin mimetic PA scaffolds on
the recovery of diabetic wounds. We analyzed reepithelializa-
tion, granulation tissue formation, blood vessel density, and
inflammatory response of full skin thickness wounds inflicted
on STZ-induced diabetic rats. In addition, we investigated
impact of heparin mimetic gel treatment on VEGF expression.
2. MATERIALS AND METHODS
2.1. Materials. 9-fluorenylmethoxycarbonyl (Fmoc) and tert-
butoxycarbonyl (Boc) protected amino acids, [4-[a-(20,40-dimethox-
yphenyl) Fmocaminomethyl]enoxy]acetamidonorleucyl-MBHA resin
(Rink amide MBHA resin), Fmoc-Asp(OtBu)-Wang resin and 2-(1H-
Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU) were purchased from NovaBiochem (8.51006.0100) and
ABCR (AB172551). Antibodies were purchased from Abcam and
Millipore. Streptozocin (STZ) were purchased from Sigma-Aldrich
(18883−66−4) and biopsy punch from Microtek Medical (Zutphen,
NL). Animals were anaesthetized with 2% Alfazyne (xylazine
hydrochloride) and 10% Alfamine (ketamine hydrochloride). All
other chemicals and materials used in this study were analytical grade
and obtained from Invitrogen, Fisher, Merck, Alfa Aesar, and Sigma-
Aldrich.
2.2. Peptide Synthesis and PA Gel Formation. Peptide
amphiphile (PA) molecules used in this study were synthesized by
solid phase peptide synthesis, as previously described.16 Briefly, rink
amide MBHA resin (for GAG-PA, K-PA) and Fmoc-Glu(OtBu)-Wang
resin (for E-PA) were used as solid support. Amino acid couplings
were performed with two equivalents of Fmoc protected amino acid,
1.95 equiv HBTU and 3 equiv of N,N-diisopropylethylamine (DIEA)
for 2 h. Fmoc removal was performed with a 20% piperidine/
dimethylformamide solution (DMF) for 20 min. 10% acetic anhydride
solution in DMF was used to block remaining free amine groups after
amino acid coupling. The p-sulfobenzoic acid was added to the side
chain of lysine to synthesize sulfonated PAs. During the synthesis of
GAG-PA, Mtt removal was performed by shaking resins with
TFA:TIS:H2O:DCM in the ratio of 5:2.5:2.5:90. PAs were cleaved
from the resin with a mixture of TFA:TIS:H2O in a ratio of 95:2.5:2.5
for 2 h. PAs were characterized by liquid chromatography−mass
spectroscopy (LC−MS). A gradient of water (0.1% formic acid or
0.1% NH4OH) and acetonitrile (0.1% formic acid or 0.1% NH4OH)
was used as the mobile phase. To purify the peptides, Agilent
preparative reverse-phase HPLC system equipped with Zorbax
Extend-C18 21.2 × 150 mm column and Zorbax SB-C8 21.2 × 150
mm column were used for basic and acidic conditions, respectively.
GAG-PA, E-PA, and K-PA were individually dissolved in distilled
water and sonicated for 10 min prior to use. Bioactive gel formation
was performed through the mixing of GAG-PA and K-PA at a 1:2
molar ratio, while nonbioactive gels were formed by mixing E-PA and
K-PA at a 1:1 molar ratio. Peptide solutions were adjusted to pH 7.4
prior to use. Net charges of the system had negative potentials for both
bioactive and nonbioactive nanofibers. Peptide mixtures were prepared
sterilized under UV light just before the experiments.
2.3. Characterization of Peptide Amphiphile Molecules.
Scanning electron microscopy (SEM) samples were prepared by
incubating, 1 wt % of GAG-PA/K-PA or E-PA/K-PA gels for 20 min
on silicon wafer. Samples were then dehydrated by immersion into
increasing concentrations of ethanol, dried in a critical point drier
(Tousimis, Autosamdri-815B), and coated with a 6 nm Au−Pd layer
prior to analysis.
Circular dichroism (CD) experiments were performed using a J-815
Jasco spectrophotometer. 3.6 × 10−4 M aqueous solutions were diluted
from 1 mM stock peptide solutions for CD spectroscopy. Measure-
ments were acquired at room temperature with 500 nm/min scanning
speed, 1 nm bandwidth and 0.1 nm data pitch within the data interval
of 300 to 190 nm. Three consecutive measurements were averaged for
each sample. The results were converted to and represented as molar
ellipticity.
Oscillatory rheology measurements were performed with an Anton
Paar Physica RM301 rheometer operating with a 25 mm parallel plate
configuration at 21 °C. One wt % of GAG-PA/K-PA or E-PA/K-PA
with total volume of 300 μL was loaded on the center of the lower
plate. The upper plate was brought to 0.5 mm gap position and the gel
was incubated for 10 min before measurement. Storage moduli (G′)
and loss moduli (G″) values were scanned at an angular frequency of
100 to 0.1 rad/s, with 0.5% shear strain. Three repeats were performed
for each gel.
2.4. Animal Models. Male Sprague−Dawley (SD) rats (weight,
300 to 350 g; age, 12 to 14 weeks) were obtained from ADACELL
Laboratory (Ankara, Turkey). Rats were exposed to a 12 h light-dark
cycle and fed a standard laboratory diet with food and water provided
ad libitum. The local Animal Experiments Committee approved all
procedures and study design. Animals were fasted overnight and given
an intraperitoneal injection of STZ (Sigma-Aldrich, St. Louis, MO) at
a dose of 45 mg/kg body weight in 0.1 mol/L sodium citrate buffer,
pH 4.5 for the induction of diabetes. Blood glucose concentrations
were monitored weekly by a GlucoDr Super Sensor Blood Glucose
Test Meter (Korea) from tail vein blood. Animals that exhibited blood
glucose levels over 20 mmol/L throughout the induction period were
considered to be stably diabetic and used for wound healing
experiments. Approximately 95% of animals were become stably
hyperglycaemic after STZ injection.
Three weeks after STZ injection, 60 male Sprague−Dawley (SD)
rats were randomly divided into 3 groups for GAG-PA/K-PA
treatment (n = 5 each for D0, D7, D9, and D14), PBS control
treatment (n = 5 each for D0, D7, D9 and D14) and E-PA/K-PA
treatment (n = 5 each for D0, D7, D9, and D14) (Figure 2D). Rats
were anesthetized by intraperitoneal injection of xylazine hydro-
chloride (Alfazyne, 10 mg/kg) and ketamine hydrochloride (Alfamine,
25 mg/kg). Prior to creation of wounds, dorsal hairs of diabetic mice
were completely shaved and the underlying skin was sterilized with
povidone iodide. Three full-thickness wounds of 6 mm diameters were
created on the dorsal skin using a biopsy skin punch for all treatment
groups (Microtek Medical, Zutphen NL). Bioactive and nonbioactive
gels were prepared immediately prior to their topical application. 1%
(w/v) of gels or saline for 300 μL were applied directly onto each
wound area and covered with Octacare nonwoven wound dressing
(OCTAMED). This wound dressing was preferred due to its elastic,
air permeable, sterile, nonallergenic, long-term powerful adhesion, and
absorbent band properties that can be easily removed from wound.
The optimization studies showed that reapplication of gel on day 2
accelerated wound healing in diabetic rats. Therefore, gels (and PBS)
were reapplied and the wounds were redressed 2 days postwounding.
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Thereafter, the animals were individually caged. At each experimental
end point (day 0, 3, 7, 9, and 14), animals were sacrificed and their
tissues were extracted for subsequent analyses. Body weights were
measured using an electronic balance on the day of wounding (day 0),
as well as on days 3, 7, 9, 12, and 14 post wounding.
2.5. Measurement of Wound Area. Wound margins were traced
on days 3, 7, 9, and 14 post wounding by using transparent papers.
The wound tracing was performed only euthanized rats. The boundary
of wound lines was traced from edge of the healthy epithelium. Wound
area was traced on the graph paper and calculated with ImageJ.
2.6. Histological Analysis. On days 3, 7, 9, and 14, diabetic rats
were sacrificed and their skin tissues were fixed with 10% formalin and
embedded in paraffin. Tissue sections (5 μm) were deparaffinized in
xylene, rehydrated through graded alcohols to distilled water, and
stained with hematoxylin and eosin (H&E). Collagen formation was
evaluated by Masson’s trichrome staining. For this purpose, sections
were initially deparaffinized, rehydrated, placed in Weigert’s
hematoxylin, and rinsed under tap water for 10 min. Sections were
then immersed into phosphomolybdic acid, aniline blue, acetic acid
and ethanol in the order provided.
All quantifications associated with H&E staining were performed
using ImageJ. Images of H&E stained tissue sections were taken with
50×magnifications by an up-right microscope (Zeiss Axio Scope A1)
and visually inspected for epithelialization scoring (0 absent, 1 weak, 2
moderate, 3 complete re-epithelialization of the wound).
Scoring was performed by three researchers who were blind to the
study design. The thickest distance between the top and the bottom of
the epithelium was measured for the quantification of epithelial
thickness. Additionally, the distance between epithelial tips were
calculated from images via measurement of length of gap between ends
of epithelial tissue. The epithelial distance measurement was
performed at days 3, 7, and 9 with ImageJ tool. On day 14, re-
epithelialization was complete for most of the samples; as such,
distance was not calculated for this day. The whole granulation tissue
area was traced and measured with ImageJ. Monocyte/macrophage
staining images were taken with 100× magnification by up-right
microscope.
2.7. Immunohistochemical Staining. Tissue sections were
deparaffinized and hydrated in graded ethanol solutions and distilled
water. Endogenous peroxidase was inactivated with 3% hydrogen
peroxide for 10 min at room temperature. Nonspecific binding sites
were blocked with 10% normal goat serum for 2 h at room
temperature. Antigens were then detected by indirect binding with
primary antibodies and HRP-conjugated secondary antibodies. Serial
sections were immunolabeled with anti-von Willebrand factor antibody
(1:400 dilution; ab6994, Abcam), alpha smooth actin antibody (1:500
dilution; ab76549, Abcam) or CD68 antibody (1:200 dilution;
ab31630, Abcam) to evaluate the degree of healing in wound tissues.
Sections were developed in 3,3′-diaminobenzidine (DAB) and
counterstained with hematoxylin.
The number of blood vessels was counted from at least 6 randomly
selected fields in each section; sections were immunolabeled with anti-
von Willebrand Factor (vWF) antibody and quantified by two
independent observers under 200× magnification. Quantifications
were performed with positive staining of vWF staining + lumen
Figure 1. (A) Self-assembled peptide amphiphile (PA) nanofibers. Chemical structures of GAG-PA, K-PA, and E-PA are shown. (B) SEM image of
GAG-PA/K-PA gel reveals the ECM like morphology of angiogenic scaffolds. (C) Photograph of the angiogenic gel formed by GAG-PA and K-PA
peptide solutions. (D) Storage and loss moduli of PA gels were measured at 0.5% of shear strain and scanned from 100 to 0.1 rad/s of angular
frequency. Rheology results showed gelation as a result of nanofibrous network formation by GAG-PA/K-PA and E-PA/K-PA at pH 7.4.
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formation. ImageJ analysis system was used to calculate the number of
vessels in each field.
2.8. Western Blot Analysis. Tissue samples were collected from
the same animals used in histological analysis at day 7 and 14; n = 3
animals were used for each GAG-PA/K-PA, E-PA/K-PA and PBS
treatment. Granulation tissues were homogenized in lysis buffer (octyl
α-D-glucopyranoside protease; ab144799, Abcam, and Protease
Inhibitor Cocktail, Thermo Scientific). Protein concentrations were
determined using a BCA Protein Assay Kit. Equal amounts of proteins
(50 μg, 15 μL) were separated by NuPAGE Tris-Acetate gels under
denaturing and nonreducing conditions and then transferred to a
PVDF membrane. The membrane was blocked with 5% nonfat milk in
TBST at room temperature for 1 h and then incubated with anti-
VEGF antibody (Abcam, ab1316, 1:400) at 4 °C overnight. After
washing in TBST, the blots were incubated with a HRP-coupled
secondary antibody (Millipore, 12−349 Goat Anti Mouse IgG,
1:1000). Signals were visualized using a chemiluminescent signal
enhancement system (Invitrogen, Novex ECL). GAPDH was used as
the internal control and treated with the same protocol (Millipore,
MAB374, 1:500). Gels were visualized by a Bio Rad VersaDoc
MP4000 imaging system and protein concentrations in gel slabs were
quantified using ImageJ. Intensities of VEGF bands were normalized
by GAPDH.
2.9. Statistical Analysis. Statistical analyses were performed using
GraphPad Prism 5. One-way and two-way ANOVA was used to
compare the differences between the groups and Dunn’s multiple
comparison test was used for posthoc correction. Error bars indicate
the standard error of the mean.
3. RESULTS
3.1. Synthesis and Characterization of PAs. Peptide
amphiphiles (PA) used in the formation of bioactive GAG-PA/
K-PA and nonbioactive E-PA/K-PA gels were synthesized by
solid phase peptide synthesis method. Lauryl-VVAGEGDK-
(pbs)S-Am (GAG-PA) was previously designed to mimic
sulfated GAGs by presenting sulfonate, hydroxyl and
carboxylate groups, while Lauryl-VVAGE-Am (E-PA) was
used as the nonbioactive control peptide (Figure 1A).
Positively charged Lauryl-VVAGK-Am (K-PA) was used to
induce nanofiber formation through electrostatic interaction
with negatively charged GAG-PA or E-PA. Peptide amphiphiles
were characterized by LC-MS and purified with preparative
HPLC (Figure S1). TEM images of these mixtures
demonstrated that nanofiber structures were formed following
the mixing of two oppositely charged peptides amphiphiles,
with average diameters of 10−20 nm, and lengths up to several
micrometers.16 SEM images revealed that the peptide nano-
fibers formed by the PA molecules exhibited a nanofibrous
network that showed similar morphology to natural ECM17
(Figure S2, Figure 1B). To analyze secondary structure of
nanofiber formation of peptide amphiphiles and their mixtures,
circular dichroism (CD) spectroscopy was employed.18 CD
results showed that the nanofibrous structures formed by the
PA molecules contained β-sheet structures as evidenced by
absorbance maximum at around 200 nm and minimum at
around 220 nm (Figure S3). Oscillatory rheology was
performed to investigate the mechanical properties of peptide
amphiphile gels (Figure 1D). The concentrations of the gels
were identical to these used in in vivo experiments. Storage (G′)
and loss (G″) moduli were scanned from 100 to 0.1 rad/s of
angular frequency and with 0.5% shear strain. Rheology results
indicated that both bioactive and nonbioactive PA molecules
formed gels as storage moduli were higher than loss moduli.
The visual observation of PA mixtures also supported the gel
formation (Figure 1C). Additionally, measurements showed
that GAG-PA/K-PA and E-PA/K-PA gels had similar
mechanical properties with stiffness values within a range of
3−8 kPa.
Figure 2. Wound closure was accelerated in GAG-PA/K-PA-treated wounds compared to controls. Photos of wounds (day 9) treated with (A)
GAG-PA/K-PA, (B) PBS−control, and (C) E-PA/K-PA. (D) Wound locations (1, 2, and 3) and treatments where C indicates PBS control; E,
nonbioactive gel; and GAG, glycosaminoglycan mimetic gel; each animal received a single treatment type across all three wounds. (E) Percentage
wound closure areas at days 3, 7, 9, and 14. One-way ANOVA analysis was performed. Statistical differences are indicated as * p < 0.05, ** p < 0.01,
and *** p < 0.001, n = 15.
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3.2. Bioactive Gel Treatment Accelerates Wound
Healing in Diabetic Rats. STZ-injected (45 mg/kg) rats
consistently became hyperglycemic after 3 weeks of diabetic
induction, and animals with blood glucose levels above 20
mmol/L were used in wound healing experiments. The body
masses and blood glucose levels of the animals showed no
statistically significant difference until the end of the
experimental periods (p > 0.05) (Figure S4).
Wound closure rates (%) were calculated for each group to
investigate whether GAG-PA/K-PA gel treatment accelerates
wound closure in diabetic rats. Following excision of full-
thickness skin lesions, no significant difference was observed in
wound closure between the three groups by day 3. At days 7, 9
and 14, wound closure was significantly accelerated in GAG-
PA/K-PA treated groups compared to E-PA/K-PA and PBS
treated controls (Figure 2A−E). Bioactive gel treated rats
exhibited rapid wound closure after day 3 and approached
nearly 80% of closure by day 14 postinjury. In contrast, E-PA/
K-PA and PBS treated diabetic control rats exhibited impaired
closure.
3.3. Bioactive Gel Treatment Accelerates Re-epitheli-
alization, Granulation Tissue Formation, and Collagen
Deposition. Keratinocyte proliferation and migration are
critical for optimal wound healing, not only because of their
role in the proliferation phase but also for their importance in
the remodeling of skin tissue. Re-epithelialization scoring,
epithelial thickness measurement and granulation tissue area
calculation were performed to analyze the healing rate of
wounds in diabetic rats (Figure 3). Although progressions of re-
epithelialization were similar between the groups on day 7,
GAG-PA/K-PA treated wounds exhibited nearly complete re-
epithelialization compared to moderate epithelialization of
controls on day 9 (Figure 3C). In E-PA/K-PA treated rats, the
dermal closure rate was similar to that in PBS treated rats. In
the later stages of wound healing, however, re-epithelialization
was complete for all groups (day 14). The distance between
epithelial tips was calculated from each group (Figure 3F).
Although not statistically significant, distance between epithelial
tips was reduced in GAG-PA/K-PA treated groups at day 7 and
9. The epidermal thickness of regenerated skin was also
measured for all groups to further investigate the effect of
bioactive gel treatment on re-epithelialization. The thickness of
bioactive PA treated epidermis was significantly greater than
control groups on days 7 and 9 (Figure 3D). Dermal
regeneration was further characterized by visualization of
granulation tissue formation both with H&E and Massons’s
trichrome staining on day 9 (Figure 3A, B). Light microscopic
examination on day 7 showed that granulation tissue per total
wound area was 58% in the GAG-PA/K-PA treated groups
whereas it was around 45% for other groups. At days 7 and 9,
Figure 3. Bioactive gel application increased re-epithelialization, granulation tissue formation and collagen deposition in diabetic wounds. Light
microscopy images of (A) H&E and (B) Masson’s trichrome stained tissue sections at day 9. (C) Re-epithelialization scoring and (D) epithelial
thicknesses of tissue sections. Quantitative analysis of (E) granulation tissue formation per total wound area and (F) distance between endothelial
tips (μm). One-way ANOVA analysis was performed. * p < 0.05, ** p < 0.01, and *** p < 0.001, scale bars = 200 μm.
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granulation tissue area per total wound area was significantly
higher in GAG-PA/K-PA treated group (Figure 3E).
Furthermore, Massons’s trichrome staining suggests that
control and E-PA/K-PA treated sections have few and poorly
Figure 4. GAG-PA/K-PA treatment induced alpha smooth muscle actin expression in diabetic wounds. α-SMA staining (brown) of wound tissues
on day 9 treated with (A) GAG-PA/K-PA, (B) control, and (C) E-PA/K-PA, with hematoxylin counterstaining of nuclei (blue). (D) Quantification
of percentage of α-SMA positive staining per granulation area at indicated time points (day 7, 9, and 14) post wounding. Two-way ANOVA was
performed. * p < 0.05, ** p < 0.01, and *** p < 0.001, scale bars = 200 μm.
Figure 5. Accelerated blood vessel intensity in GAG-PA/K-PA treated wound areas suggests that heparin mimetic peptide nanofiber treatment
induced angiogenesis. Representative von Willebrand factor staining (brown) images of wounds treated with (A) GAG-PA/K-PA, (B) PBS control,
and (C) E-PA/K-PA at day 9 and hematoxylin-blue counterstaining of nuclei. Representative examples of large vessels (arrow) as well as capillaries
(arrowheads) are shown in A−C. Quantitative analysis of number of vessels per field (D) was performed from images. Data are presented as means
± SEM *p < 0.05, **p < 0.01, ***p < 0.001, scale bars = 100 μm.
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arranged collagen bundles at the wound site on day 9 (Figure
3B). On the other hand, granulation tissue of GAG-PA/K-PA
treated wounds contained thicker and more-organized collagen
fibrils and bundles compared to controls (Figure S5). Although
there was a dramatic difference of collagen organization
between bioactive gel and controls on day 9, collagen
deposition occurs in all groups on day 14 (Figure S6).
3.4. GAG-PA/K-PA Treatment Induces Myofibroblast
Activation. Tissue sections were stained with alpha smooth
muscle actin (SMA) to monitor the transformation of fibroblast
cells to into myofibroblasts in the wound area. At day 9,
immunostaining of alpha SMA, showed that activated
fibroblasts were abundantly located at the wound margins
(Figure 4A−C). The positive immunostaining of alpha smooth
muscle actin per granulation tissue was quantified at days 7 and
9 (Figure 4D). The results of this analysis indicated that the
number of myofibroblasts and intensity of staining were
significantly higher in the granulation tissue area of GAG-PA/
K-PA-treated wounds compared to controls.
3.5. Heparin Mimetic PA Nanofibers Induce Robust
Neovascularization in Diabetic Wounds. Since angio-
genesis is a crucial event in wound healing especially for the
closure of chronic wounds, we examined the efficacy of heparin
mimetic peptide nanofibers to induce the neovascularization in
diabetic skin tissue (Figure 5A-C). As evaluated by serial
sectioning, total number of vessels per field markedly increased
in heparin mimetic peptide nanofiber treated rats at days 7, 9,
and 14 (Figure 5D). In addition to the quantification of vessel
Figure 6. VEGF expression was enhanced in GAG-PA/K-PA-treated animals, whereas lower expression was observed in control and nonbioactive
PA treated samples on day 14. The density of the bands was evaluated by ImageJ and normalized to GAPDH signal. Western blot analysis showed
that VEGF expression in the GAG-PA/K-PA-treated group was almost two folds higher than controls. Data are presented as means ± SEM **p <
0.01.
Figure 7.Monocyte/macrophage infiltration was increased in GAG-PA/K-PA treated wounds on day 9. CD68 immunostaining for (A) bioactive gel,
(B) PBS control, and (C) nonbioactive gel treated group. Brown color indicates presence of monocyte/macrophage and hematoxylin-blue
counterstaining of nuclei. (D) Quantitative analysis of number of monocyte/macrophage cells on days 3, 7, 9, and 14 post wounding. Data are
presented as means ± SEM *p < 0.05, **p < 0.01, scale bars = 50 μm.
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numbers, histological analysis showed that large vacuolar-like
vessels were seen in the wound bed of GAG-PA/K-PA-treated
tissue sections (Figure 5A). Next, we tested whether heparin
mimetic peptide nanofibers increase VEGF secretion to identify
the mechanisms underlying the effects of these gels on
promoting number of blood vessel formation.
3.6. Heparin Mimetic PA Nanofibers Promote Angio-
genesis via Induction of VEGF Expression. VEGF protein
expression was quantified in diabetic skin wounds by Western
blot analysis at day 7 (early response) and day 14 (late
response) to understand the basis of the enhanced angiogenesis
in on GAG-PA/K-PA treated animals. No significant difference
was found at VEGF protein level between groups on day 7 by
Western blot analysis (Figure S7). Higher expressions of VEGF
were observed in GAG-PA/K-PA treated animals on day 14
compared to both E-PA/K-PA and PBS control animals (Figure
6A, B). As such, it is likely that VEGF expression was
stimulated at later days of recovery by the GAG-PA/K-PA
system.
3.7. Bioactive Gel Treatment Affects Infiltration of
Inflammatory Cells. Characterization of inflammatory stage
of wounds was performed by CD68 (monocyte/macrophage
marker) staining (Figure 7A−C). Quantitative analysis showed
that number of macrophages was higher in both heparin
mimetic GAG-PA/K-PA (92.6 ± 6.8) and nonbioactive E-PA/
K-PA (91.6 ± 8.2) peptide nanofiber treated groups in contrast
to PBS treated control (46.7 ± 14.5) animals on day 3 (Figure
7D). Although the number of macrophage was 2-fold higher
than PBS control on early onset, no difference was found on
day 7. Moreover, a gradual increase in monocyte/macrophage
number was observed in GAG-PA/K-PA group on day 9.
4. DISCUSSION
Vascular complications that eventually lead to unhealed wound
ulcers are characteristic of diabetes. Reduced expression of
growth factors and impairment of angiogenesis are the main
problems associated with diabetic foot ulcers. In this study,
heparin mimetic peptide nanofibers were found to enhance
wound healing rate by accelerating angiogenesis, promoting re-
epithelialization process and stimulating the expression of
VEGF. This finding correlates with studies that report that
heparin-binding structures exhibit positive effects on wound
healing.19,20
Animal wound healing models are important biological tools
for understanding the cellular and molecular bases of tissue
repair and play a vital role in the development and validation of
potential strategies for clinical treatment. Their optimization is
therefore important for the determination of the effectiveness
of a prospective material or treatment method. While
transgenic animals are ideal for the investigation of the diabetic
wound healing process, there is an increasing amount of
evidence that shows that STZ administration can create a
suitable model of type I diabetes for wound healing
studies.21−23 In the present study, we have also implemented
minor modifications to our experimental protocol to better
accommodate the properties of the peptide amphiphile gels
used. In particular, a preliminary study had shown that gels in
uncovered wound areas may leak from the wound and mix with
each other because of the movement of the animals; as such,
potential gel mixing was prevented by coating the wounds with
a nonwoven, hypoallergenic, air-permeable elastic tape.
The main function of heparan sulfate proteoglycans
(HSPGs) is their ability to modulate angiogenesis by binding
to VEGF.24 VEGF has an extracellular matrix (ECM)-binding
domain and possesses binding affinity for HSPGs.25 In our
previous studies, we presented a heparin mimetic peptide
amphiphile (PA) nanofiber system that mimics the function of
heparan sulfate by presenting optimal arrangement of func-
tional groups (−COOH, −OH and −SO3) on nanofibrous
structures.16 In these previous studies, we also showed that the
presence of all of these functional groups within the same
system is critical for growth factor binding, and that control
peptides containing only one or two of these groups exhibit
limited functionality compared to GAG-PA.16 Furthermore,
high binding affinity of peptide system to VEGF165 rather than
VEGF121 (which lacks heparin-binding domain) showed that
growth factor binding was site specific.26 These studies also
demonstrated that this nanofiber system showed better growth
factor binding, enhanced induction of angiogenesis and
neurogenesis than control PA nanofibers in vitro.16,26,27 Our
present findings showed that wound healing rate was
accelerated in the GAG-PA/K-PA treated group compared to
PBS control and nonbioactive peptide treated groups due to
enhanced growth factor activity. As such, the increase in
regenerative capacity is attributable to the amino acid sequence
of the heparin mimetic group rather than the nanofibrous
structures of the peptide amphiphile systems.
In diabetes, phases of wound healing process do not occur in
synchrony, due to complications of the disease. We analyzed
the progress in wound healing at different time points (days 3,
7, 9, and 14) along 2 weeks after treatment application. We
found that gel treatment does not cause any difference on
healing rate at the first stage of wound healing process
(hemostasis), as the diabetic wounds began to release cytokines
and growth factors for cell recruitment.4 On the other hand,
heparin mimetic hydrogel treatment enhanced wound healing
at the inflammation and the proliferation phases.
CD68 staining was performed to observe monocyte/
macrophage recruitment to the wound area and to investigate
the extent of the immune response during the inflammation
phase. The presence of macrophage was required not only for
efficient wound repair but also for induction of neovasculariza-
tion.28,29 Reduced and abnormal vascularization was found in
wound of macrophage deficient mice.30,31 The nanofibrous
structure of the scaffolds might be one factor that induces the
early infiltration of monocyte/macrophage cells to the wound
area, as both bioactive and nonbioactive PA-treated wounds
exhibited heightened inflammatory responses on day 3;
however, this scaffold effect was temporary (Figure 7D). On
day 7, PBS treated rats had also similar number of monocyte/
macrophage with gel treated rats. Inflammatory response was
significantly higher in GAG-PA/K-PA treated group on day 9
correlated with enhanced neovascularization (Figure 5D). In
contrast, nonbioactive gel and PBS-treated rats exhibited
diminished expression of macrophages on day 9. In an efficient
wound healing process, wound macrophages disappear at the
end of inflammatory phase.28 The reduction in the higher
number of monocyte/macrophages in the GAG-PA/K-PA-
treated group on day 14 indicated that macrophage infiltration
ceased and left the wound area.
Keratinocyte migration and differentiation are inhibited in
diabetic wounds.32 Interaction of keratinocytes with fibroblasts
is crucial for proper wound healing as these interactions induce
the secretion of growth factors and cytokines.33 The results
presented here show that heparin mimetic hydrogel treatment
recruits keratinocytes to leading edge and allows their persistent
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migration. The proliferation phase is also compromised in
diabetic wounds;34 however, re-epithelialization scoring and
epithelial thicknesses results in this study indicate that tissue
proliferation was promoted in heparin mimetic hydrogel treated
wounds.
Myofibroblasts are specialized fibroblasts that play important
roles in collagen synthesis and scar formation.35 During wound
healing, myofibroblasts develop from granulation tissue and
transiently express α-SMA.36 Bioactive gel treatment was found
to recruit cells to the myofibroblastic phenotype, which is
essential for remodeling during the wound healing process. It is
notable that α-SMA expression was significantly higher in the
heparin mimetic group on day 7 and 9 (Figure 4). This result is
also in correlation with the observed increase in granulation
tissue formation (Figure 3A−F). VEGF expression is known to
induce myofibroblast transformation through the activation of
TGF-β1.37 We have also observed a 2-fold increase in VEGF
expression in heparin mimetic PA-treated animals compared to
control (Figure 6). Thus, the significant myofibroblast presence
and positive SMA staining in GAG-PA/K-PA-treated wounds
may be due to stronger VEGF expression in the wound area.
VEGF is essential for early blood vessel formation and
angiogenesis.38 Wounds of STZ induced rats had diminished
expression of VEGF compared to nondiabetic wounds.39
Western blot analysis showed that VEGF expression was
similar between samples on day 7 (Figure S8), but increased in
GAG-PA/K-PA treated wounds on day 14 (Figure 6). During
the wound healing process, VEGF expression was obtained
from many cell types such as endothelial cells, fibroblasts,
smooth muscle cells, platelets, neutrophils, and macrophages.5
The presence of high number of those cells in the wound area
contributes VEGF secretion upon heparin mimetic gel
treatment.
Increases in the number of newly formed vessels, together
with high VEGF expression patterns, suggest that heparin
mimetic gels are able to protect and stabilize the wound
environment through modulation of angiogenesis. We also
demonstrated that nonbioactive fibers had little to no influence
on wound healing, except for an increase in early macrophage
recruitment a nonsignificant trend toward delayed recovery,
suggesting that the effects observed in the GAG-PA/K-PA
group were sequence-specific. Overall, heparin mimetic
bioactive peptide nanofiber gels were found to be effective in
increasing VEGF expression and promoting vessel formation in
diabetic wounds.
5. CONCLUSION
In this study, we show the application of a previously developed
heparin mimetic peptide nanofiber system for the treatment of
diabetic wounds. This bioinspired material promoted wound
healing in the STZ-induced diabetic rat wound model. Results
presented in this study showed that heparin mimetic peptide
nanofiber treatment has a significant impact on the
inflammation and proliferation phases of the healing process.
The application of the bioactive gel formed by these peptide
nanofibers to wound area promotes angiogenesis, re-epitheli-
alization, and inflammatory response. In addition, cell recruit-
ment was accelerated and macrophage infiltration was increased
during the inflammatory phase in GAG-PA/K-PA treated rats.
A marked increase on expression of VEGF and number of
blood vessels are strong evidence of the induction of
angiogenesis in diabetic wounds. Overall, these results show
that heparin mimetic peptide nanofibers are a promising
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